Drugs / BR790
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04891653 | Jun 2021 → Jun 2023 | neoplastic disease or syndrome | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Unknown | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05715398 | Feb 2023 → Dec 2024 | non-small cell lung carcinoma | Shanghai Gopherwood Biotech Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/2 | NCT05505877 | Sep 2022 → Oct 2024 | neoplasm | Shanghai Gopherwood Biotech Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BR790 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04891653 ↗ |
| Route | Oral | “oral administration of BR790” NCT04891653 ↗ |